CN109790146B - 药物化合物 - Google Patents

药物化合物 Download PDF

Info

Publication number
CN109790146B
CN109790146B CN201780057475.6A CN201780057475A CN109790146B CN 109790146 B CN109790146 B CN 109790146B CN 201780057475 A CN201780057475 A CN 201780057475A CN 109790146 B CN109790146 B CN 109790146B
Authority
CN
China
Prior art keywords
methyl
hydroxy
oxo
phenyl
methylpropanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780057475.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109790146A (zh
Inventor
P·休伊特
M·M·麦克法兰
詹姆士·塞缪尔·沙恩·朗特里
弗兰克·布尔坎普
C·贝尔
L·普罗克特
M·D·赫尔姆
科林·奥多德
蒂莫西·哈里森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of CN109790146A publication Critical patent/CN109790146A/zh
Application granted granted Critical
Publication of CN109790146B publication Critical patent/CN109790146B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201780057475.6A 2016-07-26 2017-07-26 药物化合物 Expired - Fee Related CN109790146B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1612938.9A GB201612938D0 (en) 2016-07-26 2016-07-26 Pharmaceutical compounds
GB1612938.9 2016-07-26
PCT/GB2017/052178 WO2018020242A1 (en) 2016-07-26 2017-07-26 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
CN109790146A CN109790146A (zh) 2019-05-21
CN109790146B true CN109790146B (zh) 2022-08-23

Family

ID=56894331

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780057475.6A Expired - Fee Related CN109790146B (zh) 2016-07-26 2017-07-26 药物化合物

Country Status (15)

Country Link
US (2) US11053213B2 (enExample)
EP (1) EP3490982B1 (enExample)
JP (1) JP6986065B2 (enExample)
KR (1) KR20190034564A (enExample)
CN (1) CN109790146B (enExample)
AU (1) AU2017304761C1 (enExample)
BR (1) BR112019001253A2 (enExample)
CA (1) CA3031036A1 (enExample)
ES (1) ES2914677T3 (enExample)
GB (1) GB201612938D0 (enExample)
IL (1) IL264415B (enExample)
MX (1) MX382624B (enExample)
SG (1) SG11201900545TA (enExample)
WO (1) WO2018020242A1 (enExample)
ZA (1) ZA201900540B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
JP7402792B2 (ja) * 2017-09-26 2023-12-21 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 多発性骨髄腫を治療するための新規なｕｓｐ７阻害剤
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
CA3113547A1 (en) 2018-10-22 2020-04-30 Dana-Farber Cancer Institute, Inc. Usp7 inhibition
WO2020115501A1 (en) 2018-12-06 2020-06-11 Almac Discovery Limited Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
SG11202105911PA (en) * 2018-12-06 2021-07-29 Almac Discovery Ltd Usp19 inhibitors for use in therapy
CN114401715A (zh) * 2019-05-06 2022-04-26 瓦洛健康股份有限公司 抑制usp19
BR112022009361A2 (pt) * 2019-11-13 2022-08-09 Univ Temple Novas lactonas funcionalizadas como moduladores do receptor 7 de 5- hidroxitriptamina e seu método de uso
CN111039860B (zh) * 2019-12-02 2022-09-13 河北科技大学 2-羟基-n-(4’-氯联苯-2-基)烟酰胺的合成方法及应用
GB202001980D0 (en) * 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
USD991067S1 (en) 2020-10-17 2023-07-04 Honeywell International Inc. Modular aspirated smoke, gas, and air quality monitoring system device
GB202104097D0 (en) 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds
GEAP202516632A (en) 2022-04-22 2025-02-25 Vertex Pharma Heteroaryl compounds for the treatment of pain
GB202311227D0 (en) 2023-07-21 2023-09-06 Almac Discovery Ltd Pharmaceutical compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1230186A (zh) * 1996-07-18 1999-09-29 藤泽药品工业株式会社 吡唑并吡啶化合物及其药学的用途
CN1131862C (zh) * 1999-06-02 2003-12-24 詹森药业有限公司 经吡咯烷基、哌啶基或高哌啶基取代的(苯并二噁烷,苯并呋喃或苯并吡喃)衍生物
WO2013027001A1 (en) * 2011-08-22 2013-02-28 Takeda Pharmaceutical Company Limited Compounds and their use to treat histamine h3 related disorders
CN103930415A (zh) * 2011-09-02 2014-07-16 海布里詹尼克斯股份公司 泛素特异性蛋白酶7的选择性和可逆性抑制剂
WO2015090224A1 (zh) * 2013-12-20 2015-06-25 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2552013A1 (en) * 2011-07-27 2013-01-30 Siemens Aktiengesellschaft Reduction of noise and vibrations of an electromechanical transducer by using a modified stator coil drive signal comprising harmonic components
TWI770525B (zh) * 2014-12-30 2022-07-11 美商瓦洛健康公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1230186A (zh) * 1996-07-18 1999-09-29 藤泽药品工业株式会社 吡唑并吡啶化合物及其药学的用途
CN1131862C (zh) * 1999-06-02 2003-12-24 詹森药业有限公司 经吡咯烷基、哌啶基或高哌啶基取代的(苯并二噁烷,苯并呋喃或苯并吡喃)衍生物
WO2013027001A1 (en) * 2011-08-22 2013-02-28 Takeda Pharmaceutical Company Limited Compounds and their use to treat histamine h3 related disorders
CN103930415A (zh) * 2011-09-02 2014-07-16 海布里詹尼克斯股份公司 泛素特异性蛋白酶7的选择性和可逆性抑制剂
WO2015090224A1 (zh) * 2013-12-20 2015-06-25 中国人民解放军军事医学科学院毒物药物研究所 新型哌啶氨甲酰类化合物、制备方法及其用途

Also Published As

Publication number Publication date
RU2019105179A3 (enExample) 2020-10-19
ES2914677T3 (es) 2022-06-15
MX2019001011A (es) 2019-05-23
CN109790146A (zh) 2019-05-21
BR112019001253A2 (pt) 2019-05-07
KR20190034564A (ko) 2019-04-02
AU2017304761A1 (en) 2019-01-31
EP3490982A1 (en) 2019-06-05
AU2017304761B2 (en) 2021-06-03
WO2018020242A1 (en) 2018-02-01
US11053213B2 (en) 2021-07-06
US20220002264A1 (en) 2022-01-06
RU2019105179A (ru) 2020-08-27
US12466805B2 (en) 2025-11-11
AU2017304761C1 (en) 2021-12-09
JP2019523266A (ja) 2019-08-22
MX382624B (es) 2025-03-13
EP3490982B1 (en) 2022-04-20
CA3031036A1 (en) 2018-02-01
JP6986065B2 (ja) 2021-12-22
US20190233394A1 (en) 2019-08-01
GB201612938D0 (en) 2016-09-07
IL264415B (en) 2022-02-01
SG11201900545TA (en) 2019-02-27
ZA201900540B (en) 2022-07-27
IL264415A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
CN109790146B (zh) 药物化合物
CN115298170B (zh) 作为yap/taz-tead蛋白-蛋白相互作用抑制剂的联芳基衍生物
CN115397821B (zh) 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
TWI663153B (zh) 作為激酶抑制劑的胺基雜芳基苯甲醯胺
CN113164775A (zh) 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
CN110088096A (zh) 作为泛素特异性蛋白酶7的抑制剂的哌啶衍生物
AU2017359025A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha V integrin inhibitors
TW201713635A (zh) 環化胺磺醯基芳醯胺衍生物及其作為治療ｂ型肝炎之醫藥品之用途
CN112262139A (zh) 作为激酶抑制剂的氨基吡咯并三嗪
JP2024505261A (ja) Ｃｄｋ２阻害剤およびその使用方法
CN112135818A (zh) 4-羟基哌啶衍生物及其作为泛素特异性蛋白酶19(usp19)的抑制剂的用途
CN113950477B (zh) 颗粒体蛋白前体调节剂和其使用方法
CN117157285A (zh) 作为泛素特异性蛋白酶19(usp19)抑制剂的药物化合物
CN113365696A (zh) 药物化合物和其作为泛素特异性蛋白酶19(usp19)抑制剂的用途
JP2023027074A (ja) 複素環式プロリンアミド誘導体
TWI762545B (zh) 磺醯胺化合物及其用途
CN116917279A (zh) Btk抑制剂
RU2776482C2 (ru) Фармацевтические соединения
CN117980292A (zh) 用于治疗正粘病毒感染的取代的吡啶酮化合物
HK40068840B (zh) 稠合吡啶酮类化合物及其制备方法和应用
HK40077347A (zh) Raf激酶的抑制剂
HK40009971B (en) 1,3-thiazol-2-yl substituted benzamides
HK40008443A (en) Imidazopyrrolopyridine as inhibitors of the jak family of kinases
HK1219276A1 (zh) 二杂芳基化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220823

CF01 Termination of patent right due to non-payment of annual fee